BPGbio to Present New Immuno-Oncology Research on BPM31510 and BRG399 at SITC 2024

BPGbio, Inc., a prominent biopharmaceutical company utilizing AI and focusing on mitochondrial biology and protein homeostasis, has announced that it will present three scientific posters at the Society for Immunotherapy of Cancer (SITC) 2024 Annual Meeting. The event is scheduled to be held from November 6 to 10, 2024, in Houston, Texas. These posters will detail the latest research advancements on BPGbio’s drug candidates, BPM31510 and BRG399, in the field of immuno-oncology, showcasing their potential in cancer treatment.

The first study, titled “The Anti-tumor Response of BPM31510 is Associated with Immune Cell Regulation in the Tumor Microenvironment,” reveals that BPM31510 significantly elevates reactive oxygen species (ROS) in cancer cells, causing their destruction across various cancer types. Additionally, the study found that BPM31510 enhances the activity of cytotoxic tumor-infiltrating lymphocytes while decreasing markers of T cell exhaustion. This dual effect suggests BPM31510's potential effectiveness in treating "immunologically cold" tumors, such as glioblastoma and pancreatic cancer.

The second study, “BRG399, a Novel Oral Microtubule Binding Agent, Induces Tumor Regression and Immune Memory in an Orthotopic Glioblastoma Rat Model,” demonstrates that BRG399 treatment results in glioblastoma tumor regression and ensures 100% survival in treated rats. Furthermore, BRG399 induces an immune memory response, which prevents tumor recurrence when the surviving rats are re-challenged with glioma cancer cells.

The third study, “BRG399, a Novel Oral Microtubule Binding Agent, Exhibits Immune-Modulatory Properties Enhancing Anti-Tumor Responses,” indicates that BRG399 changes the immune cell composition within the tumor microenvironment and bloodstream. It also reduces markers of T cell exhaustion, suggesting the potential for reinvigorating immune responses against tumors. These findings highlight BRG399 as a promising candidate for combination with immunotherapies, given its dual action of killing cancer cells and enhancing immune activity.

According to Stephane Gesta, Ph.D., VP of Discovery and Translational Biology at BPGbio, these compounds, BPM31510 and BRG399, represent significant advancements in cancer therapy. They not only attack tumors but also bolster the body's immune system to continue the fight long after treatment concludes. As BRG399 progresses through preclinical trials and BPM31510 nears the end of its Phase 2b study, BPGbio will continue to utilize its NAi Interrogative Biology Platform to discover new therapeutic opportunities for other diseases.

Poster Presentation Details:
The first poster, titled “The Anti-Tumor Response of BPM31510 Is Associated with Immune Cell Regulation in the Tumor Microenvironment,” will be presented by Maria-Dorothea Nastke, Ph.D., on November 8, 2024, at 1:00 p.m. CST at Exhibit Halls A B, George R. Brown Convention Center, Houston, Texas (Abstract Number: 1312).

The second poster, “BRG399, a Novel Oral Microtubule Binding Agent, Induces Tumor Regression and Immune Memory in an Orthotopic Glioblastoma Rat Model,” will also be presented by Maria-Dorothea Nastke, Ph.D., on November 9, 2024, at 2:00 p.m. CST at the same location (Abstract Number: 1313).

The third poster, “BRG399, a Novel Oral Microtubule Binding Agent, Exhibits Immune-Modulatory Properties Enhancing Anti-Tumor Responses,” will be presented by Kaila Bennett, Ph.D., on November 9, 2024, at 3:00 p.m. CST at the same venue (Abstract Number: 1284).

BPM31510 is BPGbio's leading candidate in late-stage development for glioblastoma multiforme (GBM) and pancreatic cancer. It has shown a tolerable safety profile and potential clinical benefits in these populations. The drug’s mechanism of action was initially validated through BPGbio's NAi Interrogative Biology platform, which indicated a shift in the tumor microenvironment induced by BPM31510, modulating mitochondrial oxidative phosphorylation in highly aggressive tumors. BPM31510 has also received the FDA's Rare Pediatric Disease Designation for primary CoQ10 deficiency and Epidermolysis Bullosa (EB).

BRG399, developed by BPGbio, is being explored for its potential as a treatment for solid and liquid tumors and diseases associated with neutrophil-driven inflammation. This drug is a first-in-class, anti-tubulin agent with broad-spectrum anti-cancer activity and favorable pharmacological properties, including oral bioavailability for clinical testing. BRG399 is leading BPGbio’s new oncology drug pipeline, targeting the colchicine binding pocket in tubulin.

BPGbio stands at the forefront of a new era in medicine, using its proprietary Interrogative Biology Platform and AI to transform the understanding, diagnosis, and treatment of diseases. The company, headquartered near Boston, is committed to advancing its deep pipeline of AI-developed therapeutics across oncology, rare diseases, and neurology.